Shares of MEI Pharma (MEIP) have risen by 23% since my November 2017 article called the stock a prime turnaround candidate due to multiple material catalysts expected for its oncology-focused pipeline. On the other hand, shares have fallen by 40% since my post ASCO update in 2018 in which I highlighted ME-40's exciting prospects as a best-in-class P13K Delta inhibitor.
With shares currently on the rebound and two drug candidates in potentially registrational studies, I'm looking forward to determining if there's a near-term opportunity for readers to take advantage of.
Chart
Figure 1: MEIP daily